• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Zoetis Releases 2024 Sustainability Progress Update

    6/5/25 9:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    • Increased colleague-reported volunteer hours by 23%, making a difference for animals, those who care for them, and communities
    • Zoetis Foundation dispersed $11.3 million in grants, including funding for nearly 500 veterinary student scholarships
    • Launched strategic partnerships to address sustainability needs for dairy and beef producers
    • Responded to avian influenza challenges with science-driven solutions
    • Sourced 80.6% of global electricity from renewable sources
    • Advanced sustainable manufacturing with packaging improvements and reduced emissions

    Zoetis published its 2024 Sustainability Progress Update "Advancing Sustainability in Animal Health for a Better Future" to highlight the company's continued progress toward achieving its Driven to Care aspirations. The publication represents Zoetis' fifth year reporting on its purpose-driven actions across three pillars – Communities, Animals and the Planet – that strengthen its business by creating long-term value, enhancing stakeholder trust, and supporting sustainable growth.

    "Zoetis contributes to a healthier future for communities, animals and the planet thanks to our colleagues who demonstrate their commitment to the Driven to Care strategy and are empowered to advance our company's purpose," said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, and Chief Sustainability Officer at Zoetis and President of the Zoetis Foundation. "By embedding our sustainability strategy across our business, and through purposeful partnerships with our customers and other stakeholders, our actions address challenges at the intersection of people, animals and the environment."

    Highlights of the company's progress in 2024 include:

    Communities – Care and Collaboration

    • 20,404 hours of community-based volunteer time reported by colleagues, which represents 102% of the company's stated goal and a 23% increase from hours reported in 2023. Zoetis provides paid time off for colleagues to volunteer and support animals, their caregivers, and local communities.
    • The Zoetis Foundation disbursed $11.3 million in grants in 2024 ($26.2 million since 2021), supporting education, well-being, and livelihoods for veterinarians and farmers as well as humanitarian aid and a matching gifts program. The grantmaking in 2024 included $3.5 million in funding that will provide nearly 500 veterinary student scholarships.
    • $8.9 million invested in communities through Zoetis Inc. corporate giving; efforts included vet care access to approximately 322,000 pet owners in need and providing care to approximately 428,000 animals affected by disasters.
    • 86% colleague engagement rate driven by a culture anchored in Core Beliefs; the company's focus on colleagues includes talent development programs, mentorship and coaching, and comprehensive benefits to foster an inclusive workplace where every colleague can thrive.

    Animals – Innovation in Animal Health

    • Launched a strategic partnership with Danone, leveraging Zoetis' genetics expertise to advance the dairy industry's approach to breeding cattle for sustainability. Also, began a research collaboration with AgNext to close data gaps and meet the evolving sustainability needs of the cattle industry.
    • Introduced solutions for Highly Pathogenic Avian Influenza (HPAI) including existing vaccines used to help protect California Condors in the U.S. and trialed on five species of endangered birds in New Zealand.
    • Treated 16.7 million cows and 354.9 million chickens in Sub-Saharan Africa, exceeding goals, through the company's African Livestock Productivity and Health Advancement (A.L.P.H.A. Plus) initiative.

    Planet – The Drive to Protect our Planet

    • Continued progress toward carbon neutrality in the company's own operations, reducing total Scope 1 and 2 emissions by 26.7% from 2023. This reduction was primarily driven by increased renewable energy credits procured through a virtual power purchase agreement.
    • 80.6% of the company's global electricity is from renewable sources. The company's locations covered by renewable electricity include 15 manufacturing sites, its R&D headquarters in Kalamazoo, Michigan, and its international headquarters office in Dublin, Ireland.
    • Installed an 800kW solar array at the Rutherford manufacturing site in Australia – making it Zoetis' eighth location to generate a portion of its power through on-site solar energy.
    • Implemented new sustainable packaging solutions and reduced waste through recycled paper packaging for a cattle vaccine in Europe and replaced single use with reusable pallets and transitioned from air to sea freight in Spain.

    For more detailed disclosures on the company's sustainability programs, practices and policies, please download Zoetis' 2024 Sustainability Progress Update or visit www.zoetis.com/sustainability. Zoetis will continue to share updates on its sustainability activities, including progress against its Driven to Care aspirations, and report annually.

    About Zoetis

    As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

    DISCLOSURE NOTICES

    Forward-Looking Statements: This press release and the 2024 Sustainability Progress Update (including the 2024 SASB and ESG Index) contain forward-looking statements which reflect the current views of Zoetis with respect to: our progress toward our Driven to Care aspirations; our business plans or prospects; expectations regarding future operating or financial performance; the plans and future work of the Zoetis Foundation, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

    All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

    See the footnotes within our 2024 Sustainability Progress Update for more details regarding all calculations.

    ZTS-COR

    ZTS-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250604519690/en/

    Media Contacts:

    Jennifer Albano

    1-862-399-0810 (o)

    [email protected]

    Laura Panza

    1-973-975-5176 (o)

    [email protected]

    Investor Contacts:

    Steve Frank

    1-973-822-7141

    [email protected]

    Nick Soonthornchai

    1-973-443-2792 (o)

    [email protected]

    Get the next $ZTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    7/12/2022$205.00Overweight
    Piper Sandler
    3/9/2022$232.00 → $208.00Neutral
    Citigroup
    More analyst ratings

    $ZTS
    Financials

    Live finance-specific insights

    See more
    • Zoetis Declares Third Quarter 2025 Dividend

      The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, July 18, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The c

      5/21/25 4:15:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Announces First Quarter 2025 Results

      Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% Updates Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income t

      5/6/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nu

      3/27/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    SEC Filings

    See more
    • SEC Form SD filed by Zoetis Inc.

      SD - Zoetis Inc. (0001555280) (Filer)

      6/2/25 4:04:30 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Zoetis Inc. (0001555280) (Filer)

      5/22/25 4:26:50 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zoetis Inc. (0001555280) (Filer)

      5/21/25 4:22:57 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/13/24 5:17:36 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      1/26/24 11:49:41 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/9/23 11:37:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Zoetis with a new price target

      Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

      12/2/24 7:04:18 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Zoetis with a new price target

      BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00

      7/25/24 6:48:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Zoetis with a new price target

      Stifel reiterated coverage of Zoetis with a rating of Buy and set a new price target of $215.00 from $195.00 previously

      1/12/24 8:18:04 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

      For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

      1/13/22 10:26:13 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zoetis Releases 2024 Sustainability Progress Update

      Increased colleague-reported volunteer hours by 23%, making a difference for animals, those who care for them, and communities Zoetis Foundation dispersed $11.3 million in grants, including funding for nearly 500 veterinary student scholarships Launched strategic partnerships to address sustainability needs for dairy and beef producers Responded to avian influenza challenges with science-driven solutions Sourced 80.6% of global electricity from renewable sources Advanced sustainable manufacturing with packaging improvements and reduced emissions Zoetis published its 2024 Sustainability Progress Update "Advancing Sustainability in Animal Health for a Better Future" to high

      6/5/25 9:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Mark Stetter Elected to Zoetis Board of Directors

      Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

      5/22/25 4:15:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Declares Third Quarter 2025 Dividend

      The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company's common stock as of the close of business on Friday, July 18, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The c

      5/21/25 4:15:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Lagano Roxanne sold $110,840 worth of shares (652 units at $170.00), decreasing direct ownership by 4% to 15,129 units (SEC Form 4)

      4 - Zoetis Inc. (0001555280) (Issuer)

      6/4/25 4:31:39 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Scully Robert W converted options into 17,535 shares, increasing direct ownership by 443% to 21,489 units (SEC Form 4)

      4 - Zoetis Inc. (0001555280) (Issuer)

      5/23/25 12:14:50 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Stetter Mark

      4 - Zoetis Inc. (0001555280) (Issuer)

      5/22/25 6:32:13 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Mark Stetter Elected to Zoetis Board of Directors

      Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

      5/22/25 4:15:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

      New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu

      11/11/24 9:20:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

      Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand

      4/1/24 4:30:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care